The dietary supplement industry, particularly its botanical sector, is navigating a period of significant transition, with companies closely monitoring shifts within the U.S. Food and Drug Administration (FDA) and their potential impact in the coming year. Addressing these concerns, Hellen Oketch-Rabah, Ph.D., deputy director of the FDA’s Office of Dietary Supplement Programs (ODSP), delivered a keynote address at the American Herbal Products Association’s (AHPA) 2026 Botanical Congress in Portland, Oregon. Her remarks provided a crucial window into the agency’s evolving priorities and underscored a commitment to fostering collaborative partnerships with industry stakeholders.
Context of the AHPA Botanical Congress
The AHPA Botanical Congress serves as a vital annual gathering for professionals involved in the cultivation, manufacturing, and marketing of botanical products for dietary supplements. This year’s event, held against a backdrop of increasing regulatory scrutiny and a dynamic market landscape, provided a critical platform for dialogue between industry leaders and key regulatory officials. The attendance of Dr. Oketch-Rabah, a figure with extensive experience in botanical and supplement safety, was highly anticipated, with many seeking clarity on the FDA’s future direction.
Dr. Oketch-Rabah’s background adds significant weight to her pronouncements. Her tenure includes a role in the ODSP’s Office of Food Chemical Safety, Dietary Supplements and Innovation within the Human Foods Program, as well as previous positions at the U.S. Pharmacopeia and as a principal scientist at Herb Pharm, a well-established dietary supplement company. This diverse experience allows her to bridge the gap between regulatory requirements and the practical realities faced by the industry. Graham Rigby, president and CEO of AHPA, aptly introduced her as "one of our own," highlighting her deep understanding of the sector and her suitability to offer valuable insights.
FDA’s Core Priorities for the Supplement Industry
Dr. Oketch-Rabah articulated a clear set of strategic priorities for the ODSP, focusing on enhancing regulatory frameworks, improving industry compliance, and streamlining agency operations.
Strengthening New Dietary Ingredient (NDI) Regulations
A cornerstone of the FDA’s agenda is the reinforcement of New Dietary Ingredient (NDI) regulations. This initiative is aimed at ensuring the safety of novel ingredients entering the market. The agency plans to advance related guidances, with a specific focus on publishing comprehensive guidance concerning the safety and identity requirements for NDI notifications. This aims to provide greater clarity for manufacturers on when a formal notification is necessary and what constitutes adequate supporting data for such submissions.
The NDI process, established by the Dietary Supplement Health and Education Act of 1994 (DSHEA), requires manufacturers to submit a notification to the FDA at least 90 days before marketing a dietary ingredient that was not marketed in the United States before October 15, 1994. The intent is to allow the FDA to review the safety of the new ingredient before it enters commerce. However, the process has been subject to interpretation and industry feedback regarding the scope and depth of safety evidence required. The proposed advancements in guidance are expected to address these ambiguities, potentially leading to a more predictable and robust NDI review process.
Enhancing Compliance and Enforcement
Alongside regulatory strengthening, the FDA is intensifying its focus on compliance and enforcement. This involves a multi-pronged approach to ensure that products on the market meet established safety and labeling standards. The agency’s efforts will likely include increased monitoring of market activities, proactive investigations into non-compliant products, and a more robust system for addressing violations. This renewed emphasis on enforcement is a signal to the industry that adherence to regulations will be a primary focus in the coming years.
Historically, warning letters issued by the FDA have often cited issues related to finished dietary supplement specifications. Dr. Oketch-Rabah specifically highlighted this, emphasizing the critical role that accurate and comprehensive product specifications play in ensuring quality and safety. She defined specifications as the "central, defining characteristic of a product" and underscored that "good specifications build quality into the product." This suggests that the FDA will be scrutinizing product specifications more rigorously as a means of preventing adulteration and misbranding.
Increasing Regulatory Flexibility and Reducing Burden
In a move intended to foster a more conducive business environment, the FDA is also committed to increasing regulatory flexibility and reducing the compliance burden on the industry. This is a delicate balancing act, as the agency must uphold public health standards while also recognizing the operational challenges faced by businesses.
A notable example of this initiative is the proposed change regarding the placement of the Dietary Supplement Health and Education Act (DSHEA) disclaimer. Previously, DSHEA mandated that this disclaimer appear on all panels of a product label. Recognizing the practical difficulties and often redundant nature of this requirement, the FDA is working to establish a permanent policy allowing the disclaimer to be placed on only one panel. This pragmatic adjustment, which the agency aims to make permanent, demonstrates a willingness to adapt regulations to reflect current labeling practices and technological capabilities, thereby simplifying compliance for manufacturers. This change, if finalized, could significantly ease labeling constraints for products with complex packaging.
Modernizing Oversight Through Technology
A forward-looking aspect of the FDA’s strategy involves leveraging technological advancements to enhance its oversight capabilities.
AI and Data-Driven Approaches
The ODSP plans to harness the power of Artificial Intelligence (AI) and data analytics to modernize its oversight efforts. Dr. Oketch-Rabah indicated that these tools will provide the agency with a more comprehensive and nuanced understanding of the products available in the marketplace. By analyzing vast datasets, the FDA aims to identify emerging trends, potential safety signals, and areas of increased risk more effectively.
This data-driven approach is expected to lead to more targeted and efficient regulatory interventions. Instead of broad-stroke enforcement, the agency can potentially direct its resources to specific issues or product categories that pose the greatest risk to public health. This modernization also extends to streamlining internal agency processes, enabling the FDA to better allocate resources where they are most critically needed.
Background on Regulatory Modernization Efforts
The push for modernization within regulatory bodies is a global trend, driven by the exponential growth of information and the increasing complexity of industries. For the dietary supplement sector, which has seen significant innovation and market expansion since DSHEA’s inception, the need for updated oversight mechanisms is paramount. Previous challenges in regulatory oversight have stemmed from limitations in data processing capabilities and the manual nature of some review processes. The adoption of AI and advanced data analytics represents a significant leap forward, promising to equip the FDA with the tools necessary to keep pace with a rapidly evolving industry.
Emphasis on Collaboration and Partnership
A recurring theme in Dr. Oketch-Rabah’s address was the FDA’s commitment to a collaborative approach with the industry. She explicitly stated the ODSP’s desire to hear directly from industry stakeholders regarding their priorities and challenges. This emphasis on partnership is rooted in the belief that a shared understanding and cooperative effort are essential for building a robust and modern framework for dietary supplements.
"We believe in a collaborative partnership and a proactive relationship," Dr. Oketch-Rabah stated. "We don’t know what all is out in the industry, so it is important to work in partnership." This sentiment suggests a shift towards a more engaged and communicative relationship between the regulator and the regulated. By actively seeking industry input, the FDA aims to ensure that its regulatory strategies are not only effective in protecting public health but also practical and implementable for businesses.
Implications for the Botanical Supplement Industry
The insights shared by Dr. Oketch-Rabah carry significant implications for companies operating within the botanical supplement space. The intensified focus on NDI regulations and compliance means that manufacturers must ensure they have robust data to support the safety and identity of their ingredients, especially those that are novel or have undergone significant processing.
The commitment to increasing regulatory flexibility, such as the DSHEA disclaimer change, offers welcome relief and potential cost savings for businesses. However, this should not be misconstrued as a reduction in overall regulatory rigor. Instead, it signals a more targeted and efficient approach to oversight.
The modernization of FDA oversight through AI and data analytics suggests that the agency will have a more sophisticated ability to monitor market activities. This could lead to quicker identification of potentially problematic products or unsubstantiated claims. Consequently, companies need to ensure their internal compliance programs are equally sophisticated and proactive.
The call for collaboration is an open invitation for industry trade associations like AHPA, as well as individual companies, to actively participate in shaping the future of dietary supplement regulation. By providing constructive feedback and engaging in dialogue with the FDA, the industry can help ensure that regulatory frameworks are aligned with scientific advancements and market realities.
Broader Impact and Analysis
The FDA’s outlined strategy reflects a broader trend in regulatory governance, moving towards a more data-informed, risk-based, and collaborative approach. For the dietary supplement industry, this means an increased expectation of scientific substantiation, transparent operations, and proactive engagement with regulatory bodies.
The emphasis on finished product specifications, for instance, is a crucial area that can prevent many compliance issues. When manufacturers establish clear, scientifically sound specifications for raw materials and finished products, they inherently build quality control into their processes. This reduces the likelihood of issues related to potency, purity, and identity, which are common grounds for FDA warning letters.
The integration of AI and data analytics by the FDA is also a significant development. It suggests that the agency will be better equipped to detect patterns of non-compliance or emerging safety concerns that might have previously gone unnoticed. This could lead to a more dynamic and responsive regulatory environment.
The stated goal of reducing regulatory burden, exemplified by the DSHEA disclaimer adjustment, is a positive development that acknowledges the practical challenges faced by businesses. However, it is crucial for companies to interpret this as an opportunity to focus resources on more critical compliance areas, rather than as a signal of relaxed oversight.
In conclusion, Hellen Oketch-Rabah’s address at the AHPA Botanical Congress provided a clear and encouraging, albeit rigorous, roadmap for the future of dietary supplement regulation under the FDA. The agency’s commitment to strengthening NDI processes, enhancing compliance, embracing technological advancements, and fostering collaborative partnerships signals a proactive and adaptive approach to overseeing an industry that plays a vital role in public health and wellness. The industry’s response and engagement with these evolving priorities will be critical in shaping a future where both consumer safety and business innovation can thrive.
